Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 12

1.

PTEN expression and mutations in TSC1, TSC2 and MTOR are associated with response to rapalogs in patients with renal cell carcinoma.

Roldan-Romero JM, Beuselinck B, Santos M, Rodriguez-Moreno JF, Lanillos J, Calsina B, Gutierrez A, Tang K, Lainez N, Puente J, Castellano D, Esteban E, Climent MA, Arranz JA, Albersen M, Oudard S, Couchy G, Caleiras E, Montero-Conde C, Cascón A, Robledo M, Rodríguez-Antona C, García-Donas J; Spanish Oncology Genitourinary Group (SOGUG).

Int J Cancer. 2020 Mar 1;146(5):1435-1444. doi: 10.1002/ijc.32579. Epub 2019 Aug 9.

PMID:
31335987
2.

Immunogenicity and safety of the adjuvanted recombinant zoster vaccine in patients with solid tumors, vaccinated before or during chemotherapy: A randomized trial.

Vink P, Delgado Mingorance I, Maximiano Alonso C, Rubio-Viqueira B, Jung KH, Rodriguez Moreno JF, Grande E, Marrupe Gonzalez D, Lowndes S, Puente J, Kristeleit H, Farrugia D, McNeil SA, Campora L, Di Paolo E, El Idrissi M, Godeaux O, López-Fauqued M, Salaun B, Heineman TC, Oostvogels L; Zoster-028 Study Group.

Cancer. 2019 Apr 15;125(8):1301-1312. doi: 10.1002/cncr.31909. Epub 2019 Feb 1.

3.

Exceptional Response to Temsirolimus in a Metastatic Clear Cell Renal Cell Carcinoma With an Early Novel MTOR-Activating Mutation.

Rodríguez-Moreno JF, Apellaniz-Ruiz M, Roldan-Romero JM, Durán I, Beltrán L, Montero-Conde C, Cascón A, Robledo M, García-Donas J, Rodríguez-Antona C.

J Natl Compr Canc Netw. 2017 Nov;15(11):1310-1315. doi: 10.6004/jnccn.2017.7018.

PMID:
29118224
4.

mTOR Pathway Mutations and Response to Rapalogs in RCC-Letter.

Roldan-Romero JM, Rodríguez-Moreno JF, García-Donás J, Rodríguez-Antona C.

Clin Cancer Res. 2017 Sep 1;23(17):5320. doi: 10.1158/1078-0432.CCR-17-1280. No abstract available.

5.

A Prospective Observational Study for Assessment and Outcome Association of Circulating Endothelial Cells in Clear Cell Renal Cell Carcinoma Patients Who Show Initial Benefit from First-line Treatment. The CIRCLES (CIRCuLating Endothelial cellS) Study (SOGUG-CEC-2011-01).

García-Donas J, Leon LA, Esteban E, Vidal-Mendez MJ, Arranz JA, Garcia Del Muro X, Basterretxea L, González Del Alba A, Climent MA, Virizuela JA, Álvarez C, Sepúlveda J, Anido U, López C, Ortiz-Morales MJ, Pérez X, Rodriguez-Antona C, Rodriguez-Moreno JF, Hernando S, Castellano D.

Eur Urol Focus. 2017 Oct;3(4-5):430-436. doi: 10.1016/j.euf.2016.09.004. Epub 2016 Oct 4.

PMID:
28753791
6.

Genotyping the Host in the Battle Against Cancer.

Garcia-Donas J, Falagan S, Rodriguez-Moreno JF.

Eur Urol Focus. 2016 Dec 15;2(6):640-641. doi: 10.1016/j.euf.2016.05.002. Epub 2016 May 16. No abstract available.

PMID:
28723498
7.

Predictive biomarker candidates to delineate efficacy of antiangiogenic treatment in renal cell carcinoma.

Romero-Laorden N, Doger B, Hernandez M, Hernandez C, Rodriguez-Moreno JF, Garcia-Donas J.

Clin Transl Oncol. 2016 Jan;18(1):1-8. doi: 10.1007/s12094-015-1332-9. Epub 2015 Jul 14. Review.

PMID:
26169213
8.

Different strategies of treatment for uterine cervical carcinoma stage IB2-IIB.

Minig L, Patrono MG, Romero N, Rodríguez Moreno JF, Garcia-Donas J.

World J Clin Oncol. 2014 May 10;5(2):86-92. doi: 10.5306/wjco.v5.i2.86. Review.

9.

Renal carcinoma pharmacogenomics and predictors of response: Steps toward treatment individualization.

Garcia-Donas J, Rodriguez-Moreno JF, Romero-Laorden N, Rodriguez-Antona C.

Urol Oncol. 2015 Apr;33(4):179-86. doi: 10.1016/j.urolonc.2013.09.015. Epub 2014 Feb 1. Review.

PMID:
24495452
10.

Borderline tumours of the ovary, current controversies regarding their diagnosis and treatment.

Patrono MG, Minig L, Diaz-Padilla I, Romero N, Rodriguez Moreno JF, Garcia-Donas J.

Ecancermedicalscience. 2013 Dec 17;7:379. doi: 10.3332/ecancer.2013.379. Review.

11.

[Solitary fibrous tumor of the renal hilum: a rare a diagnosis for a not so rare clinical picture].

Rodríguez-Moreno JF, Conde E, Duran I.

Actas Urol Esp. 2012 Sep;36(8):505-6. Epub 2012 Jul 20. Spanish. No abstract available.

PMID:
22819347
12.

Is trastuzumab-induced cardiotoxicity involved in onco-cardiology outcome?

Alonso Gordoa T, García-Sáenz JÁ, Rodríguez Moreno JF, Hernández Pérez FJ, Díaz-Rubio E.

Clin Transl Oncol. 2011 Jul;13(7):451-9. doi: 10.1007/s12094-011-0682-1.

PMID:
21775272

Supplemental Content

Loading ...
Support Center